ASTRAZENECA : Jefferies downgrades to 'hold
In a research note, the analyst expresses concern at the lack of visibility surrounding the group's profit margins, but above all at the absence of any news in sight concerning its clinical portfolio.
The intermediary points out that approval of datopotamab deruxtecan (dato DXd) in lung cancer is not expected before the end of the year at best, leading him to downgrade his opinion on the stock.
On the other hand, Jefferies believes that the company's R&D projects outside oncology are still largely ignored by the market, offering potential for long-term appreciation.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction